The clinical data across the patient groups showed that patients in the T2DM combined with MS group had decreased levels of HDL‐C and elevated levels of SBP, DBP, BMI, UA, TG, HOMA‐IR, and GDF15 than patients in the T2DM group (Table 1). Here, GDF15 is linked to myeloid sarcoma.